Alcon (ALC) Q3 2025 earnings summary

Executive summary

• Q3 2025 net sales reached $2.6 billion, up 6% year-over-year, with strong momentum in Equipment and Ocular Health and successful launches of Unity VCS, PanOptix Pro, and Tryptyr.

• Core operating margin for Q3 was 20.2%, down 40 bps year-over-year; diluted EPS was $0.48, and core diluted EPS was $0.79.

• Free cash flow for the first nine months was $1.2 billion, with cash from operations at $1.6 billion.

• The company remains focused on innovation, operational excellence, and long-term growth, supported by a robust product pipeline and recent acquisitions.

• Net income for Q3 was $237 million, down 10% year-over-year, mainly due to higher tax expense.

Financial highlights

• Q3 sales reached $2.6 billion, up 6% year-over-year; nine-month net sales totaled $7.6 billion, up 4%.

• Q3 operating margin was 12.8%, down 80 bps year-over-year; core operating margin was 20.2%, down 40 bps.

• Q3 diluted EPS was $0.48, down 9% year-over-year; core diluted EPS was $0.79, down 4%.

• Free cash flow for nine months was $1.2 billion; capex was $374 million; cash and equivalents were $1.5 billion; debt was $4.7 billion.

• Gross margin for Q3 was 56.3%; nine-month gross margin was 55.5%.

Outlook and guidance

• Full-year 2025 sales guidance reaffirmed at $10.3–10.4 billion, with 4–5% constant currency growth.

• Core operating margin outlook: 19.5–20.5%; core diluted EPS: $3.05–3.15 (flat to 2% constant currency growth).

• R&D expected at the high end of 8–10% of sales, reflecting recent acquisitions.

• Management expects to offset the estimated $100 million gross impact of new tariffs in 2025 through FX and operational actions, assuming current rates and exemptions persist.

• 2026 expected to see continued acceleration from new launches, but incremental tariff impact of $50–100 million and 40 bps margin pressure from Aurion and clinical trial investments.